Education
About Us
Working with TipRanks
Follow Us
Tissue Repair Ltd (AU:TRP)
ASX:TRP
TRP Stock Chart & Stats
AU$0.38
AU$0.02(5.56%)
At close: 4:00 PM EST
AU$0.38
AU$0.02(5.56%)
Day’s Range― - ―
52-Week RangeAU$0.17 - AU$0.48
Previous CloseN/A
Volume13.59K
Average Volume (3M)93.72K
Market Cap
AU$10.58M
Enterprise Value-AU$2.34M
Total Cash (Recent Filing)AU$12.32M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding60,464,844
10 Day Avg. Volume171,402
30 Day Avg. Volume93,720
Financial Highlights & Ratios
PEG Ratio-1.06
Price to Book (P/B)0.80
Price to Sales (P/S)4.25
P/FCF Ratio-2.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSharp revenue acceleration demonstrates material commercial or licensing progress and stronger market traction for core programs. Sustained top-line growth combined with reported very high recent gross margins supports longer-term scalability and reduces pure R&D-only business risk if maintained.
Debt-free Balance SheetA debt-free capital structure materially lowers financial distress risk and provides flexibility to fund clinical development from equity or partnerships. This conservatively levered position improves survival odds during multi-year development cycles and preserves capacity for strategic deals.
Proprietary Platform & Clinical-stage ProgramsOwning a differentiated tissue repair platform and clinical-stage lead program creates durable competitive advantages and higher reuse potential across indications. Focus on chronic respiratory and fibrotic indications (eg COPD) targets large, persistent markets that can support multi-year revenue streams if clinical success follows.
Bears Say
Negative Free Cash FlowSustained negative operating and free cash flow creates recurring funding needs and elevates dilution risk. FCF worsened in 2025 versus 2024, indicating rising cash burn; reliance on external capital or partnerships is likely over the next 2–6 months absent material cash inflows.
Persistent LossesDeep, persistent operating losses limit near-term profitability and indicate a long runway to sustainable earnings. Large negative margins reduce internal funding capacity, force ongoing external financing, and make long-term planning sensitive to clinical and commercial execution outcomes.
Declining Equity / Value ErosionMaterial equity erosion over several years signals cumulative losses and shrinks the balance sheet buffer to absorb setbacks. Reduced equity increases likelihood of future capital raises, dilutes existing holders, and constrains strategic optionality during critical clinical development stages.
Tissue Repair Ltd News
TRP FAQ
What was Tissue Repair Ltd’s price range in the past 12 months?
Tissue Repair Ltd lowest share price was AU$0.17 and its highest was AU$0.48 in the past 12 months.
What is Tissue Repair Ltd’s market cap?
Tissue Repair Ltd’s market cap is AU$10.58M.
When is Tissue Repair Ltd’s upcoming earnings report date?
Tissue Repair Ltd’s upcoming earnings report date is Aug 20, 2026 which is in 178 days.
How were Tissue Repair Ltd’s earnings last quarter?
Currently, no data Available
Is Tissue Repair Ltd overvalued?
According to Wall Street analysts Tissue Repair Ltd’s price is currently Overvalued.
Does Tissue Repair Ltd pay dividends?
Tissue Repair Ltd does not currently pay dividends.
What is Tissue Repair Ltd’s EPS estimate?
Tissue Repair Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tissue Repair Ltd have?
Tissue Repair Ltd has 60,464,844 shares outstanding.
What happened to Tissue Repair Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tissue Repair Ltd?
Currently, no hedge funds are holding shares in AU:TRP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tissue Repair Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:TRP Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth AU$8.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.23%
12-Months-Change
Fundamentals
Return on Equity
-26.53%
Trailing 12-Months
Asset Growth
-24.84%
Trailing 12-Months
Company Description
Tissue Repair Ltd
Tissue Repair Ltd, a clinical stage biopharmaceutical company, developing advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia. It is developing TR-987 and other dressing/matrices, including Glucoprime technology for the treatment of chronic wounds, burns, and other complex wounds; and TR Pro+ for aftercare of minimally invasive cosmetic procedures, as well as other products for veterinary, new bandage, scaffold products, and other therapeutic indications. The company was incorporated in 2012 and is headquartered in Sydney, Australia.
Technical Analysis
Prescient Therapeutics Limited
―
Regeneus Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Bio-Gene Technology Ltd.
―